Sinclair Pharma (SPH)
SPH Share PerformanceMore
|52 week high||36.750 26/05/16|
|52 week low||26.000 28/09/16|
|52 week change||-0.125 (-0.38%)|
|4 week volume||17,870,588 27/02/17|
Latest News« previous» nextMore
22/03/2017 - 17:29 RNS
RNS Number: 2522A Sinclair Pharma PLC 22 March 2017 For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Sinclair IS Pharma Plc 2 Reason for the notification (pleas...
21/03/2017 - 09:58 StockMarketWire
Alliance Pharma has reached agreement with Sinclair Pharma for compensation in connection with the material reductio...
21/03/2017 - 09:39 StockMarketWire
Sinclair Pharma has reached an at least 5m settlement agreement with Alliance Pharma for compensation linked to the m...
21/03/2017 - 07:00 RNS
RNS Number: 0143A Alliance Pharma PLC 21 March 2017 For immediate release 21 March 2017 ALLIANCE PHARMA PLC ("Alliance" or the "Company") Settlement Agreement with Sinclair Pharma plc Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces today it has reached agreement with Sinclair Pharma plc ("Sinclair", AIM: S...
21/03/2017 - 07:00 RNS
RNS Number: 0185A Sinclair Pharma PLC 21 March 2017 Sinclair Pharma plc Preliminary results for the 12 and 18 months ended 31 December 2016 51% growth in revenues; material progress in building a leading global pure-play aesthetics company with significant, long-term growth potential 21 March 2017, Sinclair Pharma plc (AIM: SPH.L), ("Sinclair" or the "Com...
17/01/2017 - 09:27 RNS
RNS Number: 3509U Sinclair Pharma PLC 17 January 2017 Hardman Research: Demanding targets exceeded Demanding targets exceeded - Sinclair is a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics products, which target unmet clinical needs for effective, high quality, longer duration, natura...
17/01/2017 - 07:35 StockMarketWire
Sinclair Pharma is pleased with its 2016 performance, a year when it made excellent progress in its strategy to build a leadi...
17/01/2017 - 07:00 RNS
RNS Number: 2924U Sinclair Pharma PLC 17 January 2017 Pre-Close Trading Update 37.8 million 12 month revenue to December 31 2016, growth of 51%* Strong performance of all brands Successful US launch of Silhouette Instalift London, 17 January 2017 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, announce...
|Dividend yield||0 %|
Equity Research (SPH)
Sinclair Pharma plc
Sinclair has evolved into a pure-play aesthetics company with a concentrated and highly competitive portfolio of differentiated injectable aesthetics products. These products target unmet clinical...
Latest discussion posts More
“Huge volume (over 9M) traded so far this morning, and price still rising. Lokks like others are anticipating good results tomorrow. GLA”▼
“Cut and paste from official results?. Barcelona, 27th February, 2017.- Almirall, the global pharmaceutical company based in Barcelona, has posted its full-year 2016 results ...”▼
“Nice to see a positive move up (7.5%) in anticipation of the final results due out on Tuesday. This will be almost a full year as a pure play aesthetics company in what is ...”▼
Codes & Symbols
|Symbols||SPH, LSE:SPH, SPH.L, SPH:LN, LON:SPH, XLON:SPH|